Conducting Focus Groups & In Depth Interviews to Understand and Differentiate the Impact of REMS/ETASU on Prescriber Practices

Focus Groups as Used by the Food and Drug Administration

Task1-REMS_Interviewee_EmailInvitations_v5_031312

Conducting Focus Groups & In Depth Interviews to Understand and Differentiate the Impact of REMS/ETASU on Prescriber Practices

OMB: 0910-0497

Document [docx]
Download: docx | pdf

To be sent from FDA

Emailing Date: TBD

Dear ____________,

The US Food and Drug Administration has contracted with Deloitte Consulting and Global Prairie (the Deloitte Team) to conduct a comprehensive analysis of [practice settings and processes for prescribers in various specialty areas]/[ the incorporation of Risk Evaluation and Mitigation Strategies (REMS) into prescriber settings]. Our goal is to gain a better understanding of the provider settings and processes for prescribing medicines in those settings.

As part of this effort, the Deloitte Team is conducting facilitated workgroup sessions with healthcare practitioners working in different prescriber settings and specialties. You have been identified as an important candidate to provide insight on prescriber settings and practices, and we would very much appreciate your perspective for this effort.

A representative from the Deloitte Team will be contacting you in the next few days to schedule a time to talk. Interviews will take no longer than 30 minutes. Please don’t hesitate to contact me if you have any questions.

Thank you in advance for your participation.

Thank you,

Adam Kroetsch

Operations Research Analyst

US Food and Drug Administration

301-796-3842

[email protected]

To be sent from Deloitte

Dear ____,

We are writing to you from Deloitte Consulting and Global Prairie (the Deloitte Team) to follow up on a message recently sent to you by Adam Kroetsch. We are supporting the US Food and Drug Administration to conduct a comprehensive analysis of [practice settings and processes for prescribers in various specialty areas]/[ the incorporation of Risk Evaluation and Mitigation Strategies (REMS) into prescriber settings], which includes conducting facilitated workgroup sessions with healthcare practitioners to elicit their knowledge, attitudes, beliefs, and experiences related to prescriber processes and policies.

We would like to set up a time for you to talk with us in the next few weeks. Please reply to this email by TBD to confirm whether you are willing to participate in this important study. Upon receiving your confirmation, we will contact you to set up a time to talk.

Thank you in advance for your willingness to consider this request.

Most Sincerely,


Patrick Koeppl

Project Manager

240-460-9407

[email protected]


File Typeapplication/vnd.openxmlformats-officedocument.wordprocessingml.document
AuthorHausfeld-carragher, Wendi
File Modified0000-00-00
File Created2021-02-01

© 2024 OMB.report | Privacy Policy